# EDGAR Filing Document

**Accession Number:** 0000856984
**File Stem:** 0001493152-26-018222
**Filing Date:** 2026-4
**Character Count:** 13747
**Document Hash:** e43570a9281ddcbc1351add6984f0eca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-018222.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001493152-26-018222

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260421

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QHSLab, Inc.
- **CENTRAL INDEX KEY:** 0000856984
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112655906
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19041
- **FILM NUMBER:** 26876939

**BUSINESS ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407
- **BUSINESS PHONE:** (929) 379-6503

**MAIL ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITIES CORP.
- **DATE OF NAME CHANGE:** 20151119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITY CORP.
- **DATE OF NAME CHANGE:** 20151116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN BIOGENETIC SCIENCES INC
- **DATE OF NAME CHANGE:** 19940426

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (date of earliest event reported): April 21, 2026

**<u>QHSLab, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

---

| | |
|:---|:---|
| Nevada | 30-1104301 |
| (State<br> of Incorporation) | (I.R.S. Employer<br> Identification No.) |
| 901 Northpoint Parkway Suite 302 West Palm Beach<br> FL 33407 | 33407 |
| (Address of Principal Executive Offices) | (ZIP Code) |

---

Registrant's telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value** | **USAQ** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On April 21, 2026, QHSLab, Inc. (the "Company") issued a press release titled *"QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment"* A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in the press release annexed as Exhibit 99.1 is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (<u>https://twitter.com/qhslabinc</u>), LinkedIn account (<u>https://www.linkedin.com/company/65407282/</u>), Facebook account (<u>https://www.facebook.com/QHSLabs)</u> and Instagram account (<u>https://www.instagram.com/qhslabs/)</u> as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated April 21, 2026 – QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: April 21, 2026 | Date: April 21, 2026 |
| QHSLab, Inc. | QHSLab, Inc. |
|  | */s/ Troy Grogan* |
| Name: | Troy Grogan |
| Title: | CEO and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment**

 

*Unaudited Q1 2026 ISP revenue of $370,000, up from $163,000 in Q1 2025, representing 127% year-over-year growth*

 

*Growth supported by expanding provider adoption, the launch of the Q-Connect AOM and GLP-1 Support Assessment, and continued development of personalized cardiometabolic health journeys*

 

*Platform expansion into metabolic and behavioral health strengthens patient engagement and broadens recurring care opportunities*

**West Palm Beach, FL, April 21, 2026 (GLOBE NEWSWIRE) — QHSLab, Inc. (the "Company") (OTCQB: USAQ),** a digital health company focused on scalable, reimbursable care pathways for primary care and specialty practices, today provided an early second quarter 2026 update to shareholders, highlighting continued growth in its Integrated Service Program (ISP) and the launch of its Q-Connect anti-obesity medications (AOMs) and GLP-1 Support Assessment and Personalized Health Journeys Program.

For the first quarter of 2026, the Company generated unaudited ISP revenue of approximately $370,000, compared to $163,000 for the same period in 2025, representing an increase of $207,000, or 127% year-over-year growth. The increase reflects continued adoption of the Company's recurring digital care model across its growing base of provider practices.

The ISP platform enables practices to identify, monitor, and support patients across multiple conditions through digital assessments, structured reporting, and ongoing engagement outside the traditional office visit. The Company believes this model aligns clinical care with existing reimbursement pathways while reducing workflow burden for providers.

"This level of growth reflects what we are seeing in the field every day," said Troy Grogan, Chief Executive Officer of QHSLab. "Practices are looking for practical ways to deliver better care, document what they are already doing, and be appropriately reimbursed. Our platform is designed to fit into that reality without adding complexity."

As part of its continued platform expansion, QHSLab also announced the launch of Q-Connect GLP-1, a new assessment and health journeys program designed to support patients using anti-obesity medications (AOMs), including GLP-1 therapies, as well as individuals seeking to improve overall cardiometabolic health, quality of life and daily functioning.

"GLP-1 medications are an important tool, but they are only one part of the equation," said Dr. Marcos Sanchez-Gonzalez, Vice President of Scientific and Medical Affairs at QHSLab. "Patients experience changes that go beyond weight, including sleep, mood, stress, daily habits and cardiometabolic. Q-Connect GLP-1 helps patients understand and manage those changes in a structured and scalable way."

"From an endocrinology perspective, anti-obesity medications (AOMs), including GLP-1 therapies, are most effective when supported by consistent patient engagement and behavioral insight," said Reza Yavari, MD, Board Certified in Endocrinology, Diabetes and Metabolism. "Research consistently shows that patients who receive structured lifestyle support achieve better outcomes over time. What is often missing in clinical practice is a structured way to monitor how patients are adapting to treatment day-to-day. Q-Connect helps close that gap by bringing visibility to factors like sleep, stress, appetite changes, and adherence, which ultimately influence outcomes."

The assessment is designed to integrate into existing clinical workflows and can be deployed before visits, during care, or as part of ongoing population health strategies. Q-Connect also extends beyond GLP-1 use, supporting broader patient populations interested in improving lifestyle behaviors and long-term health outcomes.

"With Q-Connect, we continue to build on our core infrastructure approach," added Grogan. "This is about helping practices deliver consistent, measurement-based care across conditions, while creating a better experience for patients and providers."

The Q-Connect GLP-1 Support Assessment and Personalized Health Journeys Program is now available to QHSLab partner practices nationwide.

For additional information, including the Company's latest corporate presentation, please visit the QHSLab investor relations website at <u>https://www.qhslab.com/for-investors</u>

**About QHSLab**

QHSLab, Inc. (OTCQB: USAQ) is a digital health infrastructure company supporting independent primary care practices through workflow-integrated digital screening, clinical decision support, and care management services. The Company's platform is designed to help physicians identify and manage underdiagnosed behavioral health and chronic conditions while supporting reimbursable clinical activities that occur both during and outside traditional office visits. QHSLab generates revenue primarily through recurring service fees from participating medical practices. The Company also operates an allergy diagnostics and treatment service line under the AllergiEnd® brand. Learn more at <u>www.qhslab.com</u>

**Forward-Looking Statements**

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact:**

Olivia Giamanco

QHSLab, Inc.

(929) 379-6503

<u>ir@usaqcorp.com</u>

<u>https://twitter.com/QHSLabInc</u>